Answers are grounded in this paper and cite their sources.
Primary extramammary Paget disease (EMPD) is an intraepidermal adnexal carcinoma of the apocrine gland ducts with the potential to become invasive or metastatic. The pathogenesis of primary EMPD remains unclear; however, there have been recent studies investigating the genetic characteristics of EMPD lesions. The interaction between the programmed cell death receptor 1 (PD-1) and its ligand is one of the pathways recently reported to be a potential target in EMPD. Given the advances of immunotherapy in the field of oncology and the paucity of effective agents to treat EMPD, this article serves to shed light on recent data studying PD-1 signaling in EMPD and highlights the potential clinical use of immunotherapy for EMPD.
No takes yet. Share an insight, caveat, or question.
Mohammed Dany (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: